The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).
Connecticut ophthalmologist pleads guilty in health care fraud scheme
Unity Biotechnology announces positive data in phase 2 BEHOLD study of UBX1325 in patients with DME
New York ophthalmologists provide eye care in Haiti
